Multivalent effect of peptide functionalized polymeric nanoparticles towards selective prostate cancer targeting

Murar, Madhura; Pujals, Sílvia; Albertazzi, Lorenzo

doi:10.1039/d2na00601d

Cited by 4 publications

(1 citation statement)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, NPs have been effectively functionalized with peptides, antibodies, and aptamers, etc. for specific binding to tumor receptors, and the number of these targeting ligands bound to a NP can be much more than one [ 111 , 112 ]. For example, González-Ruíz et al evaluated the therapeutic effect of the aptamer and the peptide-labeled AuNPs loaded with 177 Lu, which significantly decreased the tumor cell viability in vitro and in vivo, and inhibited tumor progression [ 84 ].…”

Section: Radiolabeled Nanoparticles In Cancer Therapymentioning

confidence: 99%

Carrier systems of radiopharmaceuticals and the application in cancer therapy

Zhang,

Lei,

Chen

et al. 2024

Cell Death Discov.

View full text Add to dashboard Cite

Radiopharmaceuticals play a vital role in cancer therapy. The carrier of radiopharmaceuticals can precisely locate and guide radionuclides to the target, where radionuclides kill surrounding tumor cells. Effective application of radiopharmaceuticals depends on the selection of an appropriate carrier. Herein, different types of carriers of radiopharmaceuticals and the characteristics are briefly described. Subsequently, we review radiolabeled monoclonal antibodies (mAbs) and their derivatives, and novel strategies of radiolabeled mAbs and their derivatives in the treatment of lymphoma and colorectal cancer. Furthermore, this review outlines radiolabeled peptides, and novel strategies of radiolabeled peptides in the treatment of neuroendocrine neoplasms, prostate cancer, and gliomas. The emphasis is given to heterodimers, bicyclic peptides, and peptide-modified nanoparticles. Last, the latest developments and applications of radiolabeled nucleic acids and small molecules in cancer therapy are discussed. Thus, this review will contribute to a better understanding of the carrier of radiopharmaceuticals and the application in cancer therapy.

show abstract

Section: Radiolabeled Nanoparticles In Cancer Therapymentioning

confidence: 99%

Carrier systems of radiopharmaceuticals and the application in cancer therapy

Zhang,

Lei,

Chen

et al. 2024

Cell Death Discov.

View full text Add to dashboard Cite

show abstract

Surface Bio‐engineered Polymeric Nanoparticles

Haidar,

Bilek,

Akhavan

2024

Small

View full text Add to dashboard Cite

Surface bio‐engineering of polymeric nanoparticles (PNPs) has emerged as a cornerstone in contemporary biomedical research, presenting a transformative avenue that can revolutionize diagnostics, therapies, and drug delivery systems. The approach involves integrating bioactive elements on the surfaces of PNPs, aiming to provide them with functionalities to enable precise, targeted, and favorable interactions with biological components within cellular environments. However, the full potential of surface bio‐engineered PNPs in biomedicine is hampered by obstacles, including precise control over surface modifications, stability in biological environments, and lasting targeted interactions with cells or tissues. Concerns like scalability, reproducibility, and long‐term safety also impede translation to clinical practice. In this review, these challenges in the context of recent breakthroughs in developing surface‐biofunctionalized PNPs for various applications, from biosensing and bioimaging to targeted delivery of therapeutics are discussed. Particular attention is given to bonding mechanisms that underlie the attachment of bioactive moieties to PNP surfaces. The stability and efficacy of surface‐bioengineered PNPs are critically reviewed in disease detection, diagnostics, and treatment, both in vitro and in vivo settings. Insights into existing challenges and limitations impeding progress are provided, and a forward‐looking discussion on the field's future is presented. The paper concludes with recommendations to accelerate the clinical translation of surface bio‐engineered PNPs.

show abstract

Polyester nanoparticles delivering chemotherapeutics: Learning from the past and looking to the future to enhance their clinical impact in tumor therapy

Longobardi,

Moore,

Conte

et al. 2024

WIREs Nanomed Nanobiotechnol

View full text Add to dashboard Cite

Polymeric nanoparticles (NPs), specifically those comprised of biodegradable and biocompatible polyesters, have been heralded as a game‐changing drug delivery platform. In fact, poly(α‐hydroxy acids) such as polylactide (PLA), poly(lactide‐co‐glycolide) (PLGA), and poly(ε‐caprolactone) (PCL) have been heavily researched in the past three decades as the material basis of polymeric NPs for drug delivery applications. As materials, these polymers have found success in resorbable sutures, biodegradable implants, and even monolithic, biodegradable platforms for sustained release of therapeutics (e.g., proteins and small molecules) and diagnostics. Few fields have gained more attention in drug delivery through polymeric NPs than cancer therapy. However, the clinical translational of polymeric nanomedicines for treating solid tumors has not been congruent with the fervor or funding in this particular field of research. Here, we attempt to provide a comprehensive snapshot of polyester NPs in the context of chemotherapeutic delivery. This includes a preliminary exploration of the polymeric nanomedicine in the cancer research space. We examine the various processes for producing polyester NPs, including methods for surface‐functionalization, and related challenges. After a detailed overview of the multiple factors involved with the delivery of NPs to solid tumors, the crosstalk between particle design and interactions with biological systems is discussed. Finally, we report state‐of‐the‐art approaches toward effective delivery of NPs to tumors, aiming at identifying new research areas and re‐evaluating the reasons why some research avenues have underdelivered. We hope our effort will contribute to a better understanding of the gap to fill and delineate the future research work needed to bring polyester‐based NPs closer to clinical application.This article is categorized under: Therapeutic Approaches and Drug Discovery > Nanomedicine for Oncologic Disease Nanotechnology Approaches to Biology > Nanoscale Systems in Biology Therapeutic Approaches and Drug Discovery > Emerging Technologies

show abstract

Multivalent effect of peptide functionalized polymeric nanoparticles towards selective prostate cancer targeting

Abstract: The concept of selective tumor targeting using nanomedicines has been around for decades, however, no targeted nanoparticle has yet reached the clinic. A key bottleneck is the non-selectivity of targeted...

Cited by 4 publications

References 46 publications

Carrier systems of radiopharmaceuticals and the application in cancer therapy

Carrier systems of radiopharmaceuticals and the application in cancer therapy

Surface Bio‐engineered Polymeric Nanoparticles

Polyester nanoparticles delivering chemotherapeutics: Learning from the past and looking to the future to enhance their clinical impact in tumor therapy

Contact Info

Product

Resources

About